These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8388354)

  • 21. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
    Hirsh J
    Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation.
    Nordling S; Hong J; Fromell K; Edin F; Brännström J; Larsson R; Nilsson B; Magnusson PU
    Thromb Haemost; 2015 Jun; 113(6):1312-22. PubMed ID: 25740465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of unfractionated and fractionated heparin on platelet function.
    Heinrich D; Görg T; Schulz M
    Haemostasis; 1988; 18 Suppl 3():48-54. PubMed ID: 2840374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orally administered heparins prevent arterial thrombosis in a rat model.
    Pinel C; Wice SM; Hiebert LM
    Thromb Haemost; 2004 May; 91(5):919-26. PubMed ID: 15116252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight.
    Khorana AA; Sahni A; Altland OD; Francis CW
    Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):2110-5. PubMed ID: 12920044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mode of action of enoxaparin in plasma.
    Béguin S; Hemker HC
    Acta Chir Scand Suppl; 1990; 556():51-6. PubMed ID: 1963017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different pharmacokinetics, antithrombotic activity and bleeding effects of heparin and two new fragments administered in rat by subcutaneous route.
    Bergonzini GL; Bianchini P; Mascellani G; Osima B; Parma B; Volpi N
    Arzneimittelforschung; 1992 Nov; 42(11):1322-8. PubMed ID: 1337249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic use of low-molecular-weight heparins.
    Hull RD; Pineo GF
    Haemostasis; 1993 Mar; 23 Suppl 1():2-9. PubMed ID: 8388352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The internalization and release of heparins by cultured endothelial cells: the process is cell source, heparin source, time and concentration dependent.
    Hiebert LM; McDuffie NM
    Artery; 1990; 17(2):107-18. PubMed ID: 2155600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III.
    Lijnen HR; van Hoef B; Collen D
    Thromb Haemost; 1983 Aug; 50(2):560-2. PubMed ID: 6415849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.
    Young E; Cosmi B; Weitz J; Hirsh J
    Thromb Haemost; 1993 Oct; 70(4):625-30. PubMed ID: 8115988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The new heparins].
    Samama M; Babinet-Berthier A
    J Mal Vasc; 1992; 17(2):91-106. PubMed ID: 1319447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.